| Literature DB >> 30927335 |
Ann-Marie Garzinsky1, Katja Walpurgis1, Oliver Krug1,2, Mario Thevis1,2.
Abstract
To date, blood (and serum) as well as urine samples are the most commonly collected specimens for routine doping controls, which allow for the analytical coverage of an extensive set of target analytes relevant to sports drug testing programs. In the course of studies to identify potential alternative matrices to complement current testing approaches, exhaled breath (EB) has been found to offer advantageous properties especially with regard to the sample collection procedure, which is less invasive, less intrusive, and less time-consuming when compared to conventional blood and urine testing. A yet unaddressed question has been the potential contribution of oral fluid (OF) to EB samples. The current investigation focused on characterizing an electret membrane-based EB collection device concerning a potential introduction of OF during the sampling procedure. For that purpose, EB and OF samples collected under varying conditions from a total of 14 healthy volunteers were tested for the presence of abundant salivary proteins using bottom-up proteomics approaches such as SDS-PAGE followed by tryptic digestion and chromatographic-mass spectrometric analysis. The trapping baffles integrated into the mouthpiece of the EB collection device were found to effectively retain OF introduced into the unit during sample collection as no saliva breakthrough was detectable using the established analytical approach targeting predominantly the highly abundant salivary α-amylase. Since α-amylase was found unaffected by storage, smoking, food intake, and exercise, it appears to be a useful marker to reveal possible OF contaminations of EB collection devices.Entities:
Keywords: complementary matrices; exhaled breath; oral fluid; sports drug testing
Mesh:
Substances:
Year: 2019 PMID: 30927335 PMCID: PMC6973055 DOI: 10.1002/dta.2597
Source DB: PubMed Journal: Drug Test Anal ISSN: 1942-7603 Impact factor: 3.345
Figure 1SDS‐PAGE gel stained with Coomassie of pure OF samples (pOF), fortified EB samples with OF (OF) and blank EB samples (b) obtained from 4 male (m) and 4 female (f) volunteers. 1–10: Gel bands chosen for in‐gel tryptic digestion
In‐gel tryptic digestion with subsequent LC–MS/MS analysis evaluated by using proteome discoverer™ software of the most abundant bands (Figure 1); three proteins per excised band with the highest scores are listed
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1 | Keratin, type II cytoskeletal | P04264 | 14/22.98% | 40.99 | 66.0 | ~ 10 |
| Keratin, type I cytoskeletal | P35527 | 11/19.10% | 27.90 | 62.0 | ||
| Apolipoprotein A‐II | P02652 | 3/21.00% | 6.46 | 11.2 | ||
| 2 | Keratin, type II cytoskeletal 1 | P04264 | 20/25.47% | 41.62 | 66.0 | ~ 14 |
| Keratin, type I cytoskeletal 10 | P13645 | 15/22.6% | 35.28 | 58.8 | ||
| Cystatin‐S | P01036 | 6/46.1% | 33.09 | 16.2 | ||
| 3 | Myoglobin OS = Equus burchelli | P68083 | 15/81.82% | 198.62 | 17.1 | ~ 17 |
| Lipocalin‐1 | P31025 | 5/28.41% | 17.42 | 19.2 | ||
| Cystatin‐S | P01036 | 3/24.82% | 8.31 | 16.2 | ||
| 4 | Alpha‐amylase 1 | P04745 | 12/27.59% | 42.56 | 57.7 | ~ 26 |
| Apolipoprotein A‐I | P02647 | 14/56.93% | 38.71 | 30.8 | ||
| Zymogen granule protein 16 homolog B | Q96DA0 | 6/26.92% | 34.96 | 22.7 | ||
| 5 | Alpha‐amylase 1 | P04745 | 9/21.72% | 23.60 | 57.7 | ~ 31 |
| Zymogen granule protein 16 homolog B | Q96DA0 | 3/16.83% | 11.64 | 22.7 | ||
| BPI fold‐containing family A member 2 | Q96DR5 | 4/18.47% | 11.55 | 27.0 | ||
| 6 | Alpha‐amylase 1 | P04745 | 18/37.18% | 112.98 | 57.7 | ~ 58 |
| BPI fold‐containing family B member 1 | Q8TDL5 | 10/26.65% | 34.35 | 52.4 | ||
| Alpha‐1‐antitrypsin | P01009 | 5/15.07% | 17.82 | 46.7 | ||
| 7 | Alpha‐amylase 1 | P04745 | 18/36.79% | 108.30 | 57.7 | ~ 62 |
| BPI fold‐containing family B member 1 | Q8TDL5 | 11/32.44% | 48.75 | 52.4 | ||
| Serum albumin | P02768 | 12/16.42% | 43.12 | 69.3 | ||
| 8 | Serum albumin | P02768 | 30/38.59% | 127.58 | 69.3 | ~ 70 |
| Complement C3 | P01024 | 15/10.52% | 43.89 | 187.0 | ||
| Alpha‐amylase 1 | P04745 | 11/24.46% | 43.27 | 57.7 | ||
| 9 | Lactotransferrin | P02788 | 20/26.48% | 78.84 | 78.1 | ~ 100 |
| Alpha‐amylase 1 | P04745 | 14/31.51% | 76.78 | 57.7 | ||
| Serum albumin | P02768 | 15/20.2% | 55.36 | 69.3 | ||
| 10 | Mucin‐5B | Q9HC84 | 12/2.52% | 31.86 | 596.0 | ~ 130 |
| Serum albumin | P02768 | 6/9.03% | 23.18 | 69.3 | ||
| Alpha‐amylase 1 | P04745 | 6/16.05% | 17.41 | 57.7 |
In‐solution tryptic digestion with subsequent LC–MS/MS analysis evaluated by using Proteome Discoverer™ software of fortified EB samples with OF (OF) and blank EB samples (b) obtained from 3 male (m) and 2 female (f) volunteers; listed are four proteins each with the highest scores for fortified samples and each identified protein for blank samples
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| m1 (OF) | Alpha‐amylase 1 | P04745 | 17/30.72% | 64.44 | 57.7 |
| Lysozyme C | P61626 | 8/35.14% | 36.87 | 16.5 | |
| Serum albumin | P02768 | 8/16.09% | 35.18 | 69.3 | |
| Zinc‐alpha‐2‐glycoprotein | P25311 | 12/34.90% | 34.77 | 34.2 | |
| Myoglobin OS = Equus burchelli | P68083 | 18/75.32% | 101.98 | 17.1 | |
| m1 (b) | Keratin, type II cytoskeletal 1 | P04264 | 16/25.00% | 51.96 | 66.0 |
| Serum albumin | P02768 | 12/19.54% | 43.10 | 69.3 | |
| Keratin, type I cytoskeletal 10 | P13645 | 11/21.23% | 31.06 | 58.8 | |
| Myoglobin OS = Equus burchelli | P68083 | 21/88.96% | 167.44 | 17.1 | |
| f1 (OF) | Zinc‐alpha‐2‐glycoprotein | P25311 | 11/34.90% | 30.09 | 34.2 |
| Cystatin‐B | P04080 | 6/54.08% | 29.24 | 11.1 | |
| Ig alpha‐1 chain C region | P01876 | 9/19.55% | 26.48 | 37.6 | |
| Alpha‐amylase 1 | P04745 | 8/13.50% | 25.87 | 57.7 | |
| Myoglobin OS = Equus burchelli | P68083 | 18/64.94% | 105.09 | 17.1 | |
| f1 (b) | Triosephosphate isomerase | P60174 | 3/13.29% | 7.65 | 30.8 |
| Myoglobin OS = Equus burchelli | P68083 | 21/88.96% | 138.25 | 17.1 | |
| m2 (OF) | Alpha‐amylase 1 | P04745 | 19/38.75% | 72.03 | 57.7 |
| Cystatin‐B | P04080 | 7/54.08% | 31.54 | 11.1 | |
| Zinc‐alpha‐2‐glycoprotein | P25311 | 10/30.54% | 27.81 | 34.2 | |
| Ig alpha‐1 chain C region | P01876 | 8/19.55% | 22.04 | 37.6 | |
| Myoglobin OS = Equus burchelli | P68083 | 19/88.96% | 99.29 | 17.1 | |
| m2 (b) | Myoglobin OS = Equus burchelli | P68083 | 20/88.96% | 113.87 | 17.1 |
| f2 (OF) | Alpha‐amylase 1 | P04745 | 15/28.96% | 53.07 | 57.7 |
| Cystatin‐SN | P01037 | 6/30.50% | 27.05 | 16.4 | |
| Zinc‐alpha‐2‐glycoprotein | P25311 | 8/28.19% | 23.84 | 34.2 | |
| Ig alpha‐1 chain C region | P01876 | 8/19.55% | 21.54 | 37.6 | |
| Myoglobin OS = Equus burchelli | P68083 | 21/88.96% | 166.15 | 17.1 | |
| f2 (b) | Myoglobin OS = Equus burchelli | P68083 | 21/85.06% | 161.18 | 17.1 |
| m3 (OF) | Lysozyme C | P61626 | 10/35.81% | 53.55 | 16.5 |
| Alpha‐amylase 1 | P04745 | 13/19.77% | 42.83 | 57.7 | |
| Serum albumin | P02768 | 10/17.24% | 37.29 | 69.3 | |
| Cystatin‐SN | P01037 | 8/30.50% | 35.32 | 16.4 | |
| Myoglobin OS = Equus burchelli | P68083 | 18/78.57% | 120.28 | 17.1 | |
| m3 (b) | Myoglobin OS = Equus burchelli | P68083 | 23/88.96% | 158.61 | 17.1 |
Figure 2SDS‐PAGE gel stained with Coomassie of EB samples fortified with different volumes of OF
Figure 3SDS‐PAGE gel stained with Coomassie of EB samples collected without mouthpiece (wmp), EB blank samples (b) and eluates of the mouthpiece (mp) from male (m) and female (f) volunteers